Literature DB >> 24735155

Clear cell sarcoma of the kidney in a child with Fanconi anemia.

Humberto E Trejo Bittar1, Josiah E Radder, Sarangarajan Ranganathan, Abhay Srinivasan, Suneeta Madan-Khetarpal, Miguel Reyes-Múgica.   

Abstract

Patients with Fanconi anemia subgroup D1, attributable to biallelic mutations in BRCA2, have an increased risk of solid tumors. Tumors in the kidneys of these patients are almost exclusively Wilms tumor. We report the first recorded case, to our knowledge, of a Clear Cell Sarcoma of the Kidney in a patient with this cancer predisposition syndrome. We review different aspects of the need for careful clinical observation in patients of this complementation group, given their risk for malignancy.

Entities:  

Keywords:  CCSK; Clear Cell Sarcoma of Kidney; Fanconi anemia; cancer predisposition; pediatric renal cancer

Mesh:

Year:  2014        PMID: 24735155     DOI: 10.2350/14-03-1450-CR.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  3 in total

1.  Scaling up to study brca2: the zeppelin zebrafish mutant reveals a role for brca2 in embryonic development of kidney mesoderm.

Authors:  Bridgette E Drummond; Rebecca A Wingert
Journal:  Cancer Cell Microenviron       Date:  2018-04-09

2.  The zebrafish kidney mutant zeppelin reveals that brca2/fancd1 is essential for pronephros development.

Authors:  Paul T Kroeger; Bridgette E Drummond; Rachel Miceli; Michael McKernan; Gary F Gerlach; Amanda N Marra; Annemarie Fox; Kristen K McCampbell; Ignaty Leshchiner; Adriana Rodriguez-Mari; Ruth BreMiller; Ryan Thummel; Alan J Davidson; John Postlethwait; Wolfram Goessling; Rebecca A Wingert
Journal:  Dev Biol       Date:  2017-06-01       Impact factor: 3.582

3.  Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2).

Authors:  Lisa J McReynolds; Kajal Biswas; Neelam Giri; Shyam K Sharan; Blanche P Alter
Journal:  Cancer Genet       Date:  2021-10-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.